AI model for predicting outcomes in ITP with heart procedures
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This trial is testing a computer model to predict outcomes for people who have both ITP (low platelets) and heart disease needing a procedure like stenting or bypass. It aims to help doctors personalize treatment for this rare combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with immune thrombocytopenia (ITP).
- You have coronary artery disease (like chest pain or a heart attack) confirmed by a heart angiogram.
- Your ITP was diagnosed before your heart disease.
- You are not on long-term blood thinners and your low platelets are not caused by another condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two common medicines (atorvastatin and NAC) plus romiplostim to treat ITP when steroids have stopped working or stopped working. It may help raise your platelet counts.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial compares two treatments for adults recently diagnosed with immune thrombocytopenia (ITP) whose platelet count is very low and hasn't improved with standard steroids. The goal is to find a better way to raise platelet counts and reduce bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.